Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast can...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Martín, Miguel, Makhson, Anatoly, Gligorov, Joseph, Lichinitser, Mikhail, Lluch, Ana, Semiglazov, Vladimir, Scotto, Nana, Mitchell, Lada, Tjulandin, Sergei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2012
Gaiak:
Academia-Pharma Intersect
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3336828/
https://ncbi.nlm.nih.gov/pubmed/22467666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0344
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak